Results 91 to 100 of about 37,664 (239)

Inhibition of FGFR2 Signaling by Cynaroside Attenuates Liver Fibrosis

Pharmaceuticals, 2023
Liver fibrosis represents a significant health hazard with a high morbidity rate and an increased risk of liver cancer. Targeting overactivated Fibroblast growth factor receptor 2 (FGFR2) is a promising strategy to counteract collagen accumulation during
Qilin Meng, Lin Luo, Minghua Lei, Zhiqi Chen, Yuanmeng Sun, Xue Chen, Zhaodong Zhai, Yibo Zhang, Jieqiong Cao, Zijian Su, Fu Li, Jingsheng Li, An Hong, Xiaojia Chen   +13 more
doaj   +1 more source

Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies

Scientific Reports
FGFR inhibitors have been developed to inhibit FGFR activation and signal transduction; notwithstanding, currently the selection of intrahepatic cholangiocarcinoma (iCCA) patients for these drugs only relies on the detection of FGFR2 genetic alterations (
Giovanni Brandi, Valeria Relli, Marzia Deserti, Andrea Palloni, Valentina Indio, Annalisa Astolfi, Salvatore Serravalle, Alessandro Mattiaccio, Francesco Vasuri, Deborah Malvi, Chiara Deiana, Maria Abbondanza Pantaleo, Matteo Cescon, Alessandro Rizzo, Masaru Katoh, Simona Tavolari   +15 more
doaj   +1 more source

FGFR2 protein expression in breast cancer: nuclear localisation and correlation with patient genotype

BMC Research Notes, 2011
Background Single Nucleotide Polymorphisms (SNPs) in intron 2 of the Fibroblast Growth Factor Receptor Type 2 (FGFR2) gene, including rs2981582, contribute to multifactorial breast cancer susceptibility.
Thompson Alastair M, Purdie Colin A, Quinlan Philip R, Baker Lee, Palmer Colin N, Ashfield Alison M, Grant Andrew, Martin Amy J, Jordan Lee B, Berg Jonathan N   +9 more
doaj   +1 more source

FGFR2 fusion/rearrangement is associated with favorable prognosis and immunoactivation in patients with intrahepatic cholangiocarcinoma

The Oncologist
Increasing evidence highlights that fibroblast growth factor receptor 2 (FGFR2) fusion/rearrangement shows important therapeutic value for patients with intrahepatic cholangiocarcinoma (ICC).
Shaoqing Liu, Jialei Weng, Manqing Cao, Qiang Zhou, Minghao Xu, Wenxin Xu, Zhiqiu Hu, Minghao Xu, Qiongzhu Dong, Xia Sheng, Chenhao Zhou, Ning Ren   +11 more
semanticscholar   +1 more source

FGF7/FGFR2–JunB signalling counteracts the effect of progesterone in luminal breast cancer

Molecular Oncology, 2022
We have recently demonstrated that fibroblast growth factor receptor 2 (FGFR2)‐mediated signalling alters progesterone receptor (PR) activity and response of oestrogen receptor α (ER)‐positive (ER+) breast cancer (BCa) cell lines to anti‐ER agents ...
Kamil Mieczkowski, Kamila Kitowska, Marcin Braun, Barbara Galikowska-Bogut, Monika Gorska-Arcisz, Dominika Piasecka, K. Stawiski, A. Żaczek, D. Nejc, R. Kordek, H. Romanska, R. Sądej   +11 more
semanticscholar   +1 more source

Efficacy of FGFR inhibitors and combination therapies for acquired resistance in FGFR2-fusion cholangiocarcinoma

Molecular Cancer Therapeutics, 2020
The fibroblast growth factor receptor (FGFR) signaling pathway is aberrantly activated in approximately 15% to 20% of patients with intrahepatic cholangiocarcinoma.
M. Krook, Alexandria Lenyo, Max Wilberding, H. Barker, Mikayla Dantuono, Kelly M. Bailey, Hui-Zi Chen, J. Reeser, M. Wing, J. Miya, E. Samorodnitsky, Amy M. Smith, T. Dao, Dorrelyn Martin, K. Ciombor, J. Hays, A. Freud, S. Roychowdhury   +17 more
semanticscholar   +1 more source

FGFR2 accommodates osteogenic cell fate determination in human mesenchymal stem cells

Gene, 2022
The multilineage differentiation potential of human mesenchymal stem cells (hMSCs) underpins their clinical utility for tissue regeneration. Control of such cell-fate decisions is tightly regulated by different growth factors/cytokines and their cognate ...
Ying Zhang, L. Ling, Arya Ajay D/O Ajayakumar, Yating Michelle Eio, A. V. van Wijnen, V. Nurcombe, S. Cool   +6 more
semanticscholar   +1 more source

Mass Spectrometry‐Based Extracellular Vesicle Proteomics for Biomarker Discovery

Mass Spectrometry Reviews, EarlyView.
ABSTRACT Extracellular vesicle (EV) proteomics has emerged as a powerful platform for decoding intercellular communication and advancing biomarker discovery across human diseases. EVs carry proteins that reflect their cells of origin, offering a minimally invasive window into physiological and pathological processes.
Ya‐Juan Liu, Juan Peng, Chao Kang
wiley   +1 more source

Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinoma

npj Precision Oncology, 2021
Intrahepatic cholangiocarcinoma (iCCA) has emerged as a promising candidate for precision medicine, especially in the case of activating FGFR2 gene fusions.
Michael Bitzer, Stephan Spahn, Sepideh Babaei, Marius Horger, Stephan Singer, Klaus Schulze-Osthoff, Pavlos Missios, Sergios Gatidis, Dominik Nann, Sven Mattern, Veit Scheble, Konstantin Nikolaou, Sorin Armeanu-Ebinger, Martin Schulze, Christopher Schroeder, Saskia Biskup, Janina Beha, Manfred Claassen, Kristina Ruhm, Antti Poso, Nisar P. Malek   +20 more
doaj   +1 more source